Central India Chronicle

Idiopathic Pulmonary Fibrosis Market is Expected to Expand at a Healthy Growth Rate by (2022-2032), States DelveInsight | Key Companies – FibroGen, Hoffmann-La Roche Ltd., United Therapeutics

 Breaking News
  • No posts were found

Idiopathic Pulmonary Fibrosis Market is Expected to Expand at a Healthy Growth Rate by (2022-2032), States DelveInsight | Key Companies – FibroGen, Hoffmann-La Roche Ltd., United Therapeutics

January 18
19:35 2023
Idiopathic Pulmonary Fibrosis Market is Expected to Expand at a Healthy Growth Rate by (2022-2032), States DelveInsight | Key Companies - FibroGen, Hoffmann-La Roche Ltd., United Therapeutics
The Idiopathic Pulmonary Fibrosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Idiopathic Pulmonary Fibrosis pipeline products will significantly revolutionize the Idiopathic Pulmonary Fibrosis market dynamics.

DelveInsight’s “Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Idiopathic Pulmonary Fibrosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Idiopathic Pulmonary Fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Idiopathic Pulmonary Fibrosis Market Insights

 

Idiopathic Pulmonary Fibrosis Overview

The term “idiopathic” refers to a condition that has no known cause. Scarring produces stiffness in the lungs, making breathing harder. The most prevalent type of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). Itis a lung illness that produces scarring (fibrosis). Scarring produces stiffness in the lungs, making breathing harder. IPF causes irreversible and progressive lung damage, which means it becomes worse over time. Certain drugs can help to slow it down in some circumstances. Lung transplantation is occasionally indicated for persons with Idiopathic Pulmonary Fibrosis.

 

Some of the key facts of the Idiopathic Pulmonary Fibrosis Market Report: 

  • The Idiopathic Pulmonary Fibrosis market size was valued at USD 3,167 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The total diagnosed prevalent cases of IPF in the 7MMwas 194,878 cases in 2021 which are expected to rise during the study period (2019–2032)
  • The highest diagnosed prevalent cases of IPF was accounted by the US in 2021, with 94,736 cases in the7MM, which is expected to show a steep rise soon due to the improvement in diagnostic testing and increasing population
  • Among the European countries, Germany had the highest diagnosed prevalent population of IPF with 20,774 cases, followed by the UK, with 15,760 cases in 2021. On the other hand, Spainhad the lowest diagnosed prevalent population
  • Key Idiopathic Pulmonary Fibrosis Companies: FibroGen, Hoffmann-La Roche Ltd., United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB, and others
  • Key Idiopathic Pulmonary Fibrosis Therapies:Pamrevlumab, PRM-151, Tyvaso, BI 1015550, PLN-74809, GB0139, HZN-825, Garadacimab, KD025, MN-001, LYT-100, BMS-986278, ND-L02-s020, C21, and others
  • The Idiopathic Pulmonary Fibrosis epidemiology based on gender analyzed that males predominantly has the higher number of diagnosed prevalent cases than females. In 2021, 121,389 males and 73,488 females were affected by IPF in the 7MM

 

Get a Free sample for the Idiopathic Pulmonary Fibrosis Market Report – 

https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market

 

Key benefits of the Idiopathic Pulmonary Fibrosis Market report:

  1. Idiopathic Pulmonary Fibrosis market report covers a descriptive overview and comprehensive insight of the Idiopathic Pulmonary Fibrosis Epidemiology and Idiopathic Pulmonary Fibrosis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Idiopathic Pulmonary Fibrosis market report provides insights on the current and emerging therapies.
  3. Idiopathic Pulmonary Fibrosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Idiopathic Pulmonary Fibrosis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Idiopathic Pulmonary Fibrosis market.

 

Download the report to understand which factors are driving Idiopathic Pulmonary Fibrosis epidemiology trends @ Idiopathic Pulmonary Fibrosis Epidemiological Insights 

 

Idiopathic Pulmonary Fibrosis Market  

The dynamics of the Idiopathic Pulmonary Fibrosis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“The emerging therapies for the treatment of Idiopathic pulmonary fibrosis (IPF) includes a great deal of emerging drug Pamrevlumab, PRM-151, Tyvaso (treprostinil), and others. The emerging therapies in the pipeline has the potential to change the market size and manage the disease burden and progression.”

 

Idiopathic Pulmonary Fibrosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation:

The Idiopathic Pulmonary Fibrosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Idiopathic Pulmonary Fibrosis
  • Prevalent Cases of Idiopathic Pulmonary Fibrosis by severity
  • Gender-specific Prevalence of Idiopathic Pulmonary Fibrosis
  • Diagnosed Cases of Episodic and Chronic Idiopathic Pulmonary Fibrosis

 

Idiopathic Pulmonary Fibrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Idiopathic Pulmonary Fibrosis market or expected to get launched during the study period. The analysis covers Idiopathic Pulmonary Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Idiopathic Pulmonary Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Idiopathic Pulmonary Fibrosis market share @ Idiopathic Pulmonary Fibrosis market forecast

 

Idiopathic Pulmonary Fibrosis Therapies and Key Companies

  • Pamrevlumab: FibroGen
  • PRM-151: Hoffmann-La Roche Ltd.
  • Tyvaso: United Therapeutics
  • BI 1015550: Boehringer Ingelheim
  • PLN-74809: Pliant Therapeutics
  • GB0139: Galecto Biotech
  • HZN-825: Horizon Therapeutics
  • Garadacimab: CSL Behring
  • KD025: Kadmon Corporation
  • MN-001: MediciNova
  • LYT-100: PureTech
  • BMS-986278: Bristol-Myers Squibb
  • ND-L02-s020: Nitto Denko Corporation
  • C21: Vicore Pharma AB

 

Idiopathic Pulmonary Fibrosis Market Drivers

  • Management of comorbidities in Idiopathic Pulmonary Fibrosis
  • Regulatory designations

 

Scope of the Idiopathic Pulmonary Fibrosis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Idiopathic Pulmonary Fibrosis Companies: FibroGen, Hoffmann-La Roche Ltd., United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB, and others
  • Key Idiopathic Pulmonary Fibrosis Therapies: Pamrevlumab, PRM-151, Tyvaso, BI 1015550, PLN-74809, GB0139, HZN-825, Garadacimab, KD025, MN-001, LYT-100, BMS-986278, ND-L02-s020, C21, and others
  • Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies
  • Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Idiopathic Pulmonary Fibrosis Unmet Needs, KOL’s views, Analyst’s views, Idiopathic Pulmonary Fibrosis Market Access and Reimbursement 

 

Idiopathic Pulmonary Fibrosis Market Barriers

  • Absence of cure
  • Poor prognosis

 

Table of Contents 

1. Idiopathic Pulmonary Fibrosis Market Report Introduction

2. Executive Summary for Idiopathic Pulmonary Fibrosis

3. SWOT analysis of Idiopathic Pulmonary Fibrosis

4. Idiopathic Pulmonary Fibrosis Patient Share (%) Overview at a Glance

5. Idiopathic Pulmonary Fibrosis Market Overview at a Glance

6. Idiopathic Pulmonary Fibrosis Disease Background and Overview

7. Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Idiopathic Pulmonary Fibrosis 

9. Idiopathic Pulmonary Fibrosis Current Treatment and Medical Practices

10. Idiopathic Pulmonary Fibrosis Unmet Needs

11. Idiopathic Pulmonary Fibrosis Emerging Therapies

12. Idiopathic Pulmonary Fibrosis Market Outlook

13. Country-Wise Idiopathic Pulmonary Fibrosis Market Analysis (2019–2032)

14. Idiopathic Pulmonary Fibrosis Market Access and Reimbursement of Therapies

15. Idiopathic Pulmonary Fibrosis Market Drivers

16. Idiopathic Pulmonary Fibrosis Market Barriers

17.  Idiopathic Pulmonary Fibrosis Appendix

18. Idiopathic Pulmonary Fibrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Idiopathic Pulmonary Fibrosis treatment, visit @ Idiopathic Pulmonary Fibrosis Medications 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles